Home
About
- Directors and Management
- Careers
Corporate Governance
Investors
- Public Disclosure Policy
- ASX Announcements
  - 2023
  - 2022
  - 2021
  - 2020
  - 2019
  - 2018
  - 2017
  - 2016
  - 2015
  - 2014
  - 2013
  - 2012
  - 2011
  - 2010
  - 2009
  - 2008
- Financial Information & Reports
- Share Registry Information
- Analyst Coverage
- Share Information
- Anagenics in the media
- Newsletter Archive
Contact

✕

Results of Completed CK3000 Diagnostic Study

Home
Results of Completed CK3000 Diagnostic Study

Published by Tiffany McMillan on November 13, 2019

Categories

Tags

Share

Tiffany McMillan

ANAGENICS LIMITED

ASX: AN1

Suite 204, Level 2
55 Clarence Street
Sydney NSW 2000
Australia

Today’s Share Price

Latest ASX Announcements

21/02/2023 - Despatch of Retail Offer Booklet

21/02/2023 - Entitlement Offer – Letter to Ineligible Shareholders

17/02/2023 - Application for quotation of securities – AN1

*Anagenics was formerly Cellmid Limited (ASX:CDY)
© 2023 Anagenics Limited. All Rights Reserved. ABN 69 111 304 119.
Careers | Privacy Policy | Contact Us | Subscribe